Curanex Pharmaceuticals, ordinary share
US23126K1060, CURX

Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company. The Company engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offers potential benefits to patients ...

Curanex Pharmaceuticals Inc is a developmental stage pharmaceutical company. The Company engaged in discovering, developing, and commercializing botanical drugs to treat patients suffering from inflammatory diseases and to develop therapies that offers potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Its lead drug candidate, Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant. Its drug development pipelines encompass seven various therapeutic areas: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, NAFLD, gout, and acne. Phyto-N is being developed as an orally administered alternative for patients with moderate to severe ulcerative colitis. The Company's two botanical drugs include Veregen (sinecatechins) and Fulyzaq/Mytesi (crofelemer).